- For Print
- July 19, 2021
爱豆传媒. continues to stand behind the U.S. Food and Drug Administration (FDA) approval of ADUHELM™ (aducanumab-avwa) and the data from clinical studies described in the label. Eisai has been engaged in providing medical professionals in clinical practices with information to help educate about the medication’s label. Currently, we are focused on promoting ADUHELM at medical institutions and improving drug access for patients, including increasing the number of infusion centers capable of administering ADUHELM. Eisai remains committed to supporting access to ADUHELM for all appropriate patients.
Media Inquiries:
Public Relations Department,
爱豆传媒.
+81-(0)3-3817-5120